Exosome in renal cell carcinoma progression and implications for targeted therapy

Author:

Li Xinwei,Xiao Wen,Yang Hongmei,Zhang Xiaoping

Abstract

Renal cell carcinoma is a urological malignancy with a high metastatic rate, while targeted therapy for renal cell carcinoma still has much room for improvement. Some cutting-edge researches have focused on exosome in cancer treatment and there are some breakthroughs in breast cancer, lung cancer, and pancreatic cancer. Up to now, exosome in renal cell carcinoma progression and implications for targeted therapy has been under research by scientists. In this review, we have summarized the structure, formation, uptake, functions, and detection of exosomes, classified the mechanisms of exosomes that cause renal cell carcinoma progression, and listed the promising utilization of exosomes in targeted therapy for renal cell carcinoma. In all, based on the mechanisms of exosomes causing renal cell carcinoma progression and borrowing the successful experience from renal cell carcinoma models and other cancers, exosomes will possibly be a promising target for therapy in renal cell carcinoma in the foreseeable future.

Publisher

Frontiers Media SA

Reference73 articles.

1. Renal cell carcinoma for the nephrologist;Perazella;Kidney Int,2018

2. Lipids as targets for renal cell carcinoma therapy;Stepanovska Tanturovska;Int J Mol Sci,2023

3. High expression of DNTTIP1 predicts poor prognosis in clear cell renal cell carcinoma;Wang;Pharmacogenomics Pers Med,2023

4. Immunotherapy in renal cell carcinoma: the future is now;Deleuze;Int J Mol Sci,2020

5. Renal cell carcinoma;Hsieh;Nat Rev Dis Primers,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3